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Abstract: Increased generation of reactive oxygen species (ROS) is a significant 
pathological feature in the brains of patients with Alzheimer’s disease (AD). Experimental 
evidence indicates that inhibition of brain ROS could be beneficial in slowing the 
neurodegenerative process triggered by amyloid-beta (Abeta) aggregates. The angiotensin 
II AT1 receptor is a significant source of brain ROS, and AD patients have an increased 
brain angiotensin-converting enzyme (ACE) level, which could account for an excessive 
angiotensin-dependent AT1-induced ROS generation. Therefore, we analyzed the impact 
of ACE inhibition on signs of neurodegeneration of aged Tg2576 mice as a transgenic 
animal model of AD. Whole genome microarray gene expression profiling and biochemical 
analyses demonstrated that the centrally active ACE inhibitor captopril normalized the 
excessive hippocampal ACE activity of AD mice. Concomitantly, the development of 
signs of neurodegeneration was retarded by six months of captopril treatment. The 
neuroprotective profile triggered by captopril was accompanied by reduced amyloidogenic 
processing of the amyloid precursor protein (APP), and decreased hippocampal ROS, 
which is known to enhance Abeta generation by increased activation of beta- and  
gamma-secretases. Taken together, our data present strong evidence that ACE inhibition 
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with a widely used cardiovascular drug could interfere with Abeta-dependent 
neurodegeneration. 
Keywords: Alzheimer’s disease; amyloid precursor protein; angiotensin-converting 
enzyme; AT1 receptor; captopril; neurodegeneration; Tg2576 mouse model 
 
1. Introduction 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. The 
number of patients affected by AD worldwide is expected to grow substantially in the coming years 
due to increasing life expectancy [1]. However, available treatment options for AD are limited and 
ineffective to modify disease progression [2]. Research efforts of drug development aim to target 
major pathological features of AD, i.e., the deposition of extracellular senile plaques of aggregated 
amyloid-beta (Aβ), and the formation of neurofibrillary tangles of aggregated hyperphosphorylated tau 
protein [2]. Neuropathological hallmarks of AD are considered to contribute synergistically to the 
process of cognitive decline and neurodegeneration [3]. 
Increased generation of reactive oxygen species (ROS) in the brain of AD patients is a direct 
consequence of Aβ-induced toxicity, which is triggered by the amyloidogenic processing of the 
amyloid precursor protein (APP) by sequential β-secretase and γ-secretase cleavage [4,5]. Increased 
oxidative stress promotes oxidative damage to proteins, lipids, DNA and RNA, all of which seem to 
contribute to neuronal dysfunction culminating finally in neuronal damage and cognitive impairment [6]. 
While Aβ contributes to the generation of ROS in AD brain, the increased oxidative stress could 
trigger a vicious cycle of ROS-dependent enhancement of APP cleavage, Aβ oligomerization and 
memory loss [7,8]. From those data, treatment strategies that combat enhanced ROS generation in 
mitochondria and cytosol appear as a promising approach in AD treatment [9–12].  
By stimulation of the AT1 receptor, angiotensin II is a major contributor to cellular ROS  
generation [13–15]. Angiotensin II-dependent ROS generation is also active in neurons and brain, and 
plays a fundamental role in angiotensin II-dependent actions in the central nervous system [16–18]. In 
addition to the AT1 receptor, angiotensin II also activates the AT2 receptor, which could exert 
neuroprotection [19]. However, neuroprotective AT2 receptor activation appears to be compromised in 
the brain of AD patients by AD-related AT2 protein aggregation resulting in dysfunctional AT2 
protein oligomers, which could enhance neurodegeneration [20,21]. 
The brain has a fully functional angiotensin system that mediates local generation of angiotensin II 
by the angiotensin-converting enzyme, ACE [22]. The ACE gene is a candidate gene, which could 
influence AD risk [23]. In addition, some studies found that AD patients have a higher frequency of 
the ACE gene D/D genotype, and the D-allele is associated with an increased serum ACE level, and 
predisposes to amnestic mild cognitive impairment [24,25]. In agreement with a putative role of  
ACE in AD pathogenesis, ACE protein level and activity were found increased in the brain of AD 
patients [26–28].  
Despite the association of ACE with AD pathology, the role of ACE in AD is not clear because 
experimental data had shown that ACE is capable of promoting the degradation of Aβ [29]. These 
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findings have raised concern about the use of ACE inhibitors in AD patients [29]. However, recent 
data from ACE deficient mice and some experimental AD models do not support the notion that ACE 
exerts a major role in the turnover of Aβ in vivo [30–32]. Likewise, ACE inhibition did not increase 
Aβ plaque load in some animal models of AD [31,32]. Together, these data argue against a detrimental 
role of ACE inhibition in AD by promoting Aβ plaque formation. In agreement with these findings, 
epidemiological data from patient studies showed that ACE inhibitors as a class do not increase the 
incidence of AD [33]. Moreover, some selected ACE inhibitors could even be beneficial by reducing 
the risk of dementia and AD progression [34,35]. Those AD protective effects of ACE inhibitors led to 
the hypothesis that brain-penetrating ACE inhibitors could exert protection against cognitive decline 
independent of blood pressure lowering [34,35].  
Although experimental evidence also indicated beneficial effects of a brain-penetrating ACE 
inhibitor on prevention of cognitive decline [36], the effect of central ACE inhibition on brain Aβ 
deposition is not clear. Therefore, we investigated the impact of ACE inhibition on Aβ-related 
pathology and neurodegeneration. We chose Tg2576 mice, which express the amyloid precursor 
protein variant APP695 with the Swedish double mutation under control of the neuron-specific prion 
protein promoter [37]. These mice develop substantial Aβ plaque load and Aβ plaque-associated 
neuronal degeneration starting at an age of 12 months [20,37]. To investigate the effect of ACE 
inhibition on Aβ plaque-related pathology, we treated 12 month-old Tg2576 mice for six months with 
the centrally active ACE inhibitor captopril. The effect of captopril treatment on Aβ plaque 
development and signs of neurodegeneration was monitored by immunohistological analyses. 
Concomitantly, gene expression changes in the hippocampus were determined by whole genome 
microarray gene expression profiling. Results of our study revealed that ACE inhibition with captopril 
had the capacity to retard the development of Aβ plaques and Aβ-related signs of neurodegeneration.  
2. Results and Discussion 
2.1. ACE Inhibition with Captopril Slowed Aβ Plaque Accumulation of AD Mice 
The impact of ACE inhibition on Aβ plaque load was determined with Tg2576 mice as AD model. 
Aβ plaque load was detected in the hippocampus by immunohistology with Aβ-specific antibodies on 
brain sections from 18 month-old Tg2576 mice treated with or without the centrally active captopril 
for six months (Figure 1). Brain sections representing the mean Aβ plaque load of each group show 
that a captopril-treated Tg2576 mouse had a substantially smaller area of hippocampal Aβ plaques 
compared to the untreated age-matched Tg2576 control (Figure 1a). Quantitative assessment of the 
antibody-stained area revealed a 58.4% ± 15.6% reduced Aβ plaque load in the hippocampus of 
captopril-treated Tg2576 mice compared to age-matched controls (Figure 1b). For comparison,  
12 month-old Tg2576 mice were almost devoid of Aβ plaques, at the age when captopril treatment was 
initiated (Figure 1). These findings indicate that ACE inhibition with captopril could slow the  
aging-dependent accumulation of Aβ plaques in brain of Tg2576 mice. 
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Figure 1. Angiotensin-converting enzyme (ACE) inhibition with captopril slowed Aβ 
plaque accumulation of Alzheimer’s disease (AD) mice. (a) Immunohistological analysis 
of Aβ plaque load in the hippocampus of a 12 month-old untreated Tg2576 mouse  
(Tg-12mo), an untreated 18 month-old Tg2576 mouse (Tg-18mo), and an 18 month-old 
Tg2576 mouse treated for six months with the centrally active ACE inhibitor captopril  
(Tg-18mo-ACEI); bar: 200 μm; (b) Quantitative assessment of hippocampal Aβ plaque 
area (±s.d., n = 4 mice/group; A,B p < 0.001 vs. Tg-12mo; C p < 0.01 vs. Tg-18mo; ANOVA 
and Tukey’s Multiple Comparison Test). 
 
2.2. Whole Genome Microarray Gene Expression Profiling of Hippocampal Genes of AD Mice upon 
ACE Inhibition with Captopril  
We determined hippocampal gene expression changes of Tg2576 mice, which could account for the 
captopril-mediated slowing of Aβ plaque accumulation. Hippocampal RNA was isolated, processed 
for microarray gene expression profiling and hybridized to whole genome microarrays (Affymetrix 
GeneChip Mouse Genome MG430 2.0 Array) with more than 45,000 probe sets [38,39]. Scanning 
revealed uniform quality of gene chips as documented by a similar number of probe sets present, 
comparable 3'/5' ratio of house-keeping genes such as Gapdh, and average signal intensity after 
normalization to a target value of 600 (Figure 2a). 
We searched for significantly different probe sets between 18 month-old captopril-treated and  
age-matched untreated Tg2576 mice. Stringent data filtering identified 454 probe sets with 
significantly higher signal intensity in captopril-treated compared to untreated Tg2576 mice (≥+2-fold 
difference; p ≤ 0.01) while the signal intensity of 104 probe sets was lower of captopril-treated mice 
(≤−2-fold difference; p ≤ 0.01) compared to the age-matched 18-month-old Tg2576 control group 
(Figure 2b, Tables S1 and S2). Thus, whole genome microarray gene expression profiling 
demonstrated that captopril treatment for six months had led to a significant modification of 
hippocampal gene expression. 
Next, we analyzed whether captopril was capable to modify disease-related gene expression in AD 
mice. To determine genes involved in AD pathology, we focused on probe sets that were decreased 
during the accumulation of Aβ plaques, because those genes could reflect AD-related neuronal 
degeneration and concomitant loss of neuronal processes [20,21]. To identify those genes that were 
down-regulated during Aβ plaque accumulation, we compared the gene expression profile of 18 
month-old Tg2576 mice with high Aβ plaque load with the gene expression profile of 12 month-old 
Tg2576 mice with low Aβ plaque load (cf. Figure 1). A Venn diagram shows that Aβ plaque 
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accumulation in the hippocampus of 18 month-old Tg2576 mice was accompanied by the  
down-regulation of 175 probe sets relative to 12 month-old Tg2576 mice because those probe sets had 
a significantly higher signal intensity in 12 month-old mice (Figure 2c and Table S3). The Venn 
diagram also illustrates that more than 53% of those hippocampal genes (i.e., 93 probe sets), were 
significantly increased in ACEI-treated 18 month-old Tg2576 mice, towards the pre-treatment level of 
12 month-old mice (Figure 2c and Table S4). That observation indicates that captopril could preserve 
the expression level of a substantial number of genes, which were down-regulated during Aβ plaque 
accumulation of AD mice.  
Figure 2. Whole genome microarray gene expression profiling of hippocampal genes of 
AD mice. (a) Hippocampal whole genome microarray gene expression profiling of 18 and 
12 month-old Tg2576 (Tg-18mo and Tg-12mo) mice without or with ACE inhibitor 
(ACEI) treatment by captopril for six months. Hippocampal RNA from four mice was 
pooled for one gene chip, and two gene chips are presented for each group; (b) Number of 
significantly different probe sets of 18 month-old captopril-treated Tg2576 mice compared 
to untreated 18 month-old Tg2576 mice with p ≤ 0.01, and ≥+2-fold (up) or ≤−2-fold 
(down) difference; (c) The Venn diagram illustrates that more than 53% (i.e., 93 probe 
sets) of significantly increased hippocampal genes of 12 month-old Tg2576 mice compared 
to 18 month-old Tg2576 mice, showed concordant up-regulation in ACEI-treated  
18 month-old Tg2576 mice.  
 
2.3. Captopril Prevented the Down-Regulation of Genes Involved in Neuronal  
Regeneration and Cognition 
Gene ontology (GO) analysis was used to categorize those genes that were preserved by captopril 
treatment, but down-regulated during Aβ plaque accumulation of Tg2576 mice.  
GO analysis identified that 38 AD-related probe sets that were preserved by captopril, had 
established functions in neuronal regeneration and cognition. Identified gene products belonged to all 
major cellular components, i.e., nucleus, cytoplasm, and plasma membrane (Figure 3 and Table S5). A 
heat map visualizes signal intensities of identified probe sets to illustrate the preservation of neuronal 
gene expression by captopril (Figure 3 and Table S5).  
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Figure 3. Captopril prevented the AD-related down-regulation of hippocampal genes 
involved in neuronal regeneration and cognition. A heat map visualizes signal intensities 
(log2-transformed data, centered to the median value) of significantly different probe sets 
of hippocampal genes involved in neuronal regeneration and cognition, which were  
down-regulated during Aβ plaque accumulation of 18 month-old Tg2576 mice and 
preserved by treatment with the ACE inhibitor (ACEI) captopril. Probe sets of 12  
month-old Tg2576 mice are also shown to illustrate pre-treatment condition. Analysis of 
variance with p-values is presented as Table S5. 
 
2.4. ACE Inhibition Promoted Signs of Neuronal Regeneration and Up-Regulated the Expression of 
Genes Involved in the Formation of Neuronal Membrane and Neuronal Processes 
Captopril prevented the Aβ-induced down-regulation of neuronal genes. We next asked whether 
captopril “actively” up-regulated hippocampal gene expression over the expression level of the  
12 month-old Tg2576 control group. Microarray data filtering identified eleven hippocampal genes 
detected by 13 different probes, which were significantly up-regulated by captopril and categorized by 
GO terms “neuronal membrane” and “neuronal processes” (Figure 4a,b). 
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Figure 4. ACE inhibition promoted signs of neuronal regeneration and up-regulated  
the expression of genes involved in the formation of neuronal membrane and neuronal 
processes. (a,b) Microarray gene expression data of hippocampal genes categorized by 
gene ontology (GO) terms “neuronal membrane” (a), and “neuronal processes” (b), which 
were up-regulated by captopril treatment over the expression level of untreated  
12 month-old Tg2576 controls (*** p < 0.001, ** p < 0.01 and * p < 0.05 vs. Tg-12mo; 
ANOVA and Tukey’s Multiple Comparison Test, no false discovery correction; the 
average signal intensity from two gene chips is presented as -fold of Tg-12mo, with RNA 
pooled from four mice for one gene chip). The following probe sets were identified: 
1456863_at (Epha4), 1421929_at (Epha4), 1450120_at (Scn1a), 1423597_at (Atp3a2), 
1423559_at (Kcnc1), 1441728_at (Scn1a), 1422834_at (Kcnd2), 1437107_at (Rab6b), 
1426777_a_at (Wasl), 1449961_at (Rph3a), 1456656_at (Veli1), 1456911_at (Clasp2), 
1418431_at (Kif5b); (c,d) Immunoblot detection of hippocampal protein level of Scn1a (c) 
and Kcnc1 (d). Left panels show quantitative data evaluation (±s.d.; n = 4 mice/group;  
A p < 0.05 (c), A p < 0.01 (d), and B p < 0.001 vs. Tg-12mo (c,d); C p < 0.001 vs. Tg-18mo 
(c,d); ANOVA and Tukey’s Multiple Comparison Test). Middle/right panels show a 
representative immunoblot experiment; (e) Immunohistological detection of Epha4 in 
hippocampal CA1 neurons of an 18 month-old captopril-treated (ACEI) Tg2576 mouse 
compared to untreated 18 month-old (Tg-18mo) and 12 month-old (Tg-12mo) Tg2576 
mice. Nuclei were stained with hematoxylin (HE), bar 25 μm; (f) Immunofluorescence 
detection of Epha4 with Epha4-specific antibodies (green) in hippocampal CA1 neurons of 
an 18 month-old captopril-treated (ACEI) Tg2576 mouse compared to untreated 18 month-old 
and 12 month-old Tg2576 (Tg) mice. Nuclei were stained with DAPI (blue), bar 25 μm. 
Immunohistological (e) and immunofluorescence (f) experiments are representative of four 
mice/group; (g) Hippocampal Epha4 content from different groups of Tg2576 mice was 
quantified by direct binding assay with anti-Epha4 antibodies followed by detection with 
125I-labeled secondary antibodies (±s.d.; n = 4 mice/group; A p < 0.01 and B p < 0.001 vs. 
Tg-12mo; C p < 0.001 vs. Tg-18mo; ANOVA and Tukey’s Multiple Comparison Test);  
(h) Immunoblot detection of hippocampal Rab6b protein of the different treatment groups. 
The upper panel shows quantitative data evaluation (±s.d.; n = 4 mice/group; A p < 0.01 
and B p < 0.05 vs. Tg-12mo; C p < 0.001 vs. Tg-18mo; ANOVA and Tukey’s Multiple 
Comparison Test), and middle and lower panels show a representative immunoblot experiment. 
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Figure 4. Cont. 
 
Among up-regulated gene products involved in formation of the “neuronal membrane”, a literature 
search identified several genes, which were previously shown to be reduced in AD animal models or 
AD patients, i.e., Epha4 [40], Scn1a [41], and Kcnc1 [42]. Protein detection by immunoblot was used 
to validate some of the microarray gene expression data with different cohorts of mice. Immunoblotting 
showed that captopril had prevented the AD-related down-regulation of hippocampal Scn1a, i.e., the 
sodium channel, voltage gated, type I, alpha (Figure 4c). Moreover, captopril had promoted a 
significant increase in hippocampal Scn1a protein content over the level of 12 month-old Tg2576 mice 
(Figure 4c). Similar results were obtained with Kcnc1, i.e., the potassium voltage gated channel,  
Shaw-related subfamily, member 1 (Figure 4d). 
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To further validate microarray data, we focused on Epha4, the Ephrin type-A receptor 4, which is 
reduced in the hippocampus of AD mice at an early stage, before the onset of overt cognitive 
impairment [40]. Epha4 is also reduced in hippocampal tissue from AD patients [40]. 
Immunohistological analysis confirmed the microarray data for Epha4 and showed a high protein level 
of Epha4 in hippocampal CA1 neurons of an 18 month-old captopril-treated Tg2576 mouse compared 
to untreated 12 month-old and 18 month-old Tg2576 mice (Figure 4e). Similar results were obtained 
by immunofluorescence detection of Epha4 (Figure 4f). Moreover, immunofluorescence analysis 
revealed that captopril treatment had promoted the regeneration of Epha4-positive CA1 neuronal 
processes, which showed degeneration in 18 and 12 month-old Tg2576 mice (Figure 4f, left panels vs. 
right panel). Those findings complement previous data, which linked the AD-related down-regulation 
of Epha4 to neuronal degeneration and synapse loss [40]. Quantitative assessment of hippocampal 
Epha4 protein further confirmed that captopril had up-regulated the Epha4 protein content over the 
level of untreated 12 month-old Tg2576 mice (Figure 4g). 
In agreement with the capacity of captopril to promote signs of neuronal regeneration, captopril 
treatment also led to an increased hippocampal Rab6b level, a protein expressed in neuronal processes, 
while Rab6b was decreased in untreated Tg2576 mice with increasing age (Figure 4h). Taken together, 
our data strongly suggest that captopril treatment retarded the AD-related decline of neuronal gene 
expression and triggered signs of neuronal regeneration. 
2.5. Captopril Treatment Prevented the AD-Related Up-Regulation of ACE and Reduced the 
Hippocampal Angiotensin II Level of AD Mice 
In view of the neuro-regenerative potential of the ACE inhibitor captopril, we investigated the 
hippocampal expression of ACE in AD mice because the ACE level is also significantly increased in 
the brains of AD patients and correlates directly with disease stage and Aβ load [28,43]. Microarray 
gene expression data showed that the aging-dependent increase in Aβ plaque load of Tg2576 mice was 
accompanied by a substantial rise in hippocampal ACE gene expression (Figure 5a). That increase in 
ACE gene expression was completely prevented by captopril (Figure 5a). 
Concomitantly, ACE activity measurement showed that captopril-treated mice had a significantly 
lower hippocampal ACE activity than age-matched untreated Tg2576 mice (Figure 5b). Immunoblot 
analysis with ACE-specific antibodies confirmed gene expression data and showed that hippocampal 
ACE protein level was normalized by captopril (Figure 5c). In agreement with ACE inhibition, 
captopril treatment was accompanied by a significantly reduced hippocampal angiotensin II level 
compared to untreated 18 month-old AD mice (Figure 5d). Taken together, captopril treatment had 
prevented the Aβ-related increase in hippocampal ACE protein and ACE activity of AD mice. 
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Figure 5. Captopril prevented the up-regulation of ACE and reduced the hippocampal 
angiotensin II level of AD mice. (a) Microarray gene expression data of ACE gene 
expression (±s.d.; n = 2 gene chips/group, with RNA from four mice pooled for one gene 
chip; * p < 0.05 for Affymetrix ID 1427034_at (left), and ** p < 0.01 for Affymetrix ID 
1451911_a_at (right), vs. Tg-18mo; * p < 0.05 for Affymetrix ID 1451911_a_at, vs.  
Tg-12mo; ANOVA and Tukey’s Multiple Comparison Test); (b) Hippocampal ACE 
activity of 18 month-old Tg2576 (Tg) mice was normalized by captopril (ACEI) treatment 
(±s.d.; n = 4 mice/group; A p < 0.01 vs. Tg-12mo; B p < 0.001 vs. Tg-18mo; ANOVA and 
Tukey’s Multiple Comparison Test); (c,d) Quantitative immunoblot analysis of ACE 
protein level (c), and angiotensin II peptide level (d) of different groups of AD mice (±s.d.; 
n = 4 mice/group; A p < 0.001 vs. Tg-12mo, B p < 0.001 vs. Tg-18mo (c), and C p < 0.01 vs. 
Tg-12mo, D p < 0.001 vs. Tg-18mo (d); ANOVA and Tukey’s Multiple Comparison Test); 
(e) Immunofluorescence analysis with anti-ACE and anti-Aβ antibodies revealed vascular 
localization of ACE (green) and Aβ (red) in hippocampal vessels of untreated and treated 
18 month-old Tg2576 mice. Nuclei were stained with DAPI (blue; bar 25 μm);  
(f) Immunohistological detection of ACE in hippocampal CA1 neurons of 12 and  
18 month-old Tg2576 (Tg) mice treated without or with captopril (ACEI). Nuclei  
were stained with hematoxylin (HE), bar: 25 μm. Immunofluorescence (e) and 
immunohistological (f) data are representative of four mice/group. 
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2.6. ACE Protein in Hippocampal Vessels and Neurons of AD Mice Could Account for a Hippocampal 
Action of Captopril 
Previous data indicated that ACE was localized in the perivascular region of brain cortical  
vessels of AD patients [27,28]. To localize the ACE protein in brain of Tg2576 mice, we used 
immunofluorescence microscopy. Immunofluorescence analysis with ACE-specific antibodies 
localized the ACE protein in hippocampal vessels of untreated and captopril-treated 18 month-old 
Tg2576 mice (Figure 5e). The ACE protein was localized in close proximity to vascular Aβ deposits in 
a representative vessel of an untreated 18 month-old Tg2576 mouse (Figure 5e, upper panel), while the 
vessel of a captopril-treated Tg2576 mouse showed a reduced vascular Aβ load (Figure 5e, lower panel). 
In addition to vascular cells, immunohistological analysis localized the ACE protein also in cell 
soma of hippocampal CA1 neurons of Tg2576 mice (Figure 5f). In agreement with immunoblot data, 
the hippocampal ACE protein level was substantially increased in untreated 18 month-old Tg2576 
mice whereas ACE immunostaining was less in the captopril-treated Tg2576 mouse (Figure 5f). Thus, 
Tg2576 mice resemble AD patients by showing increased ACE protein level with advancement of AD 
pathology [27,28,43]. Notably, the up-regulation of ACE could be a direct consequence of increased 
Aβ plaque load [28,43,44]. Treatment with captopril prevented the Aβ-related ACE protein  
up-regulation and reduced the angiotensin II generation in the hippocampus of AD mice.  
Figure 6. Treatment of AD mice with a predominantly peripheral-acting ACE inhibitor.  
(a) Hippocampal ACE activity of 12 and 18 month-old Tg2576 mice treated without or 
with enalapril (Enal) for six months (±s.d.; n = 4 mice/group; *** p < 0.001 and ** p < 0.01 
vs. Tg-12mo; ANOVA and Tukey’s Multiple Comparison Test); (b) Hippocampal Epha4 
content of Tg2576 mice treated without or with enalapril (Enal) was determined by direct 
binding assay with anti-Epha4 antibodies followed by detection with 125I-labeled secondary 
antibodies (±s.d.; n = 4 mice/group; *** p < 0.001 and * p < 0.05 vs. Tg-12mo; ANOVA 
and Tukey’s Multiple Comparison Test); (c) Comparable peripheral ACE inhibition by 
enalapril and captopril was shown by renal ACE activity measurement of Tg2576  
mice treated for six months with captopril (Capto) or enalapril (Enal) as indicated  
(±s.d.; n = 4 mice/group; *** p < 0.001 vs. Tg-18mo; ANOVA and Tukey’s Multiple  
Comparison Test). 
 
That effect could be related to a central action of captopril because treatment of Tg2576 mice with a 
predominantly peripheral-acting ACE inhibitor, enalapril (enalaprilat), for six months did not significantly 
alter the hippocampal ACE activity of 18 month-old Tg2576 mice (Figure 6a). In addition, enalapril 
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did not prevent the down-regulation of hippocampal Epha4, an indicator of neuronal degeneration 
(Figure 6b). As a control, peripheral actions of enalapril and captopril were comparable, as documented by 
the inhibition of renal ACE activity (Figure 6c). 
2.7. Co-Localization of the AT1 Receptor with Aβ in Hippocampal Neurons of AD Mice 
The Aβ-related increase in ACE protein [28,43,44] could enhance the angiotensin II-mediated 
activation of the AT1 receptor in brain of AD mice. Since the brain AT1 receptor stimulates Aβ 
generation by enhancing the amyloidogenic processing of APP [45], we determined the localization of 
the AT1 receptor in Tg2576 mice, and asked for the potential co-localization of AT1 with Aβ in the 
hippocampus of AD mice (Figure 7a). We focused on the hippocampal CA1 region because of its high 
sensitivity to AD-related neurodegeneration [20,21]. Moreover, CA1 neurons of aged AD mice had a 
high level of ACE protein (cf. Figure 5f). Immunofluorescence microscopy revealed substantial AT1 
immunoreactivity in hippocampal CA1 neurons of an untreated 18 month-old Tg2576 mouse  
(Figure 7a). The AT1-positive neurons were localized in close proximity to Aβ plaques (Figure 7a), a 
trigger of ACE [43,44]. 
Figure 7. Co-localization of the AT1 receptor with Aβ in hippocampal neurons of AD 
mice. (a) Immunofluorescence localization of AT1 (green) and Aβ (red) in hippocampal 
neurons of an untreated 18 month-old Tg2576 (Tg) mouse. Nuclei were stained with DAPI 
(blue), bar: 25 μm; (b) Immunohistological detection of AT1 in the hippocampus of  
12 month-old, and 18 month-old Tg2576 (Tg) mice treated without or with the ACE 
inhibitor (ACEI) captopril as indicated. Nuclei were stained with hematoxylin, HE  
(bar: 25 μm); (c) Immunofluorescence analysis revealed cytosolic Aβ of AT1-positive CA1 
neurons of an 18 month-old captopril-treated (ACEI) Tg2576 mouse. Intact neuronal 
processes of AT1-positive neurons could reflect the neuroregenerative activity of captopril. 
Nuclei were stained with DAPI (blue), bar 25 μm. Immunofluorescence (a,c) and 
immunohistological (b) data are representative of four mice/group. 
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In addition to 18 month-old AD mice with high Aβ plaque load, AT1 receptor-positive hippocampal 
CA1 neurons were also detected by immunohistological staining in mice with lower Aβ plaque level, 
i.e., untreated 12 month-old and captopril-treated 18 month-old Tg2576 mice (Figure 7b). 
We used immunofluorescence microscopy to localize AT1 in CA1 neurons of captopril-treated 
Tg2576 mice. Analogous to Epha4-positive CA1 neurons of captopril-treated mice (cf. Figure 4e,f), 
AT1-positive CA1 neurons of captopril-treated mice displayed intact neuronal processes, even in  
the presence of cytosolic Aβ (Figure 7c). This observation could be another indication for the  
neuro-protective and neuro-regenerative potential of the ACE inhibitor captopril. 
Taken together, our data are compatible with the notion that the Aβ-induced increase in ACE 
protein of aged AD mice leads to enhanced hippocampal angiotensin II generation, which could 
promote AT1 receptor activation of adjacent neurons and subsequent AT1-dependent Aβ  
generation [45]. Vice versa, inhibition of ACE-dependent angiotensin II generation by captopril could 
block the activation of those hippocampal AT1 receptors. 
2.8. Captopril Treatment Reduced Hippocampal ROS and Protein Oxidation 
AT1 receptor activation by angiotensin II is a substantial trigger of brain ROS [16–18], and ROS 
enhances the amyloidogenic processing of APP as well as Aβ plaque formation [7,8]. Therefore, we 
asked whether inhibition of ACE-dependent angiotensin II generation by captopril could affect the 
level of hippocampal ROS. We determined the amount of hippocampal superoxide content as a major 
ROS form by dihydroethidium (DHE) staining (Figure 8a). Dihydroethidium staining revealed an 
aging-dependent increase in the superoxide content of hippocampal CA1 neurons of untreated 18 
month-old Tg2576 mice with high Aβ plaque load compared to 12 month-old Tg2576 mice with low 
Aβ plaque load (Figure 8a). This increase in superoxide generation was largely prevented by captopril 
treatment (Figure 8a).  
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Figure 8. Captopril treatment reduced hippocampal ROS and protein oxidation. (a) Increased 
superoxide generation of 18 month-old Tg2576 (Tg-18mo) mice was normalized by 
captopril (ACEI) treatment as determined by dihydroethidium staining (DHE) of 
hippocampal sections, bar: 25 μm. The lower panel presents relative DHE fluorescence 
levels (±s.d.; n = 4 mice/group; A,B p = 0.001 vs. Tg-12mo and Tg-18mo-ACEI; ANOVA 
and Tukey’s Multiple Comparison Test); (b) The increase in hippocampal 3-nitrotyrosine 
content of 18 month-old Tg2576 mice (Tg-18mo) was prevented by captopril (±s.d.;  
n = 4 mice/group; A p < 0.001 vs. Tg-12mo and B p < 0.01 vs. Tg-18mo-ACEI; ANOVA 
and Tukey’s Multiple Comparison Test). 
 
In agreement with decreased superoxide generation, captopril treatment also led to a reduced 
protein oxidation, i.e., the aging-related increase in hippocampal 3-nitrotyrosine content of  
18 month-old Tg2576 mice, a marker of protein oxidation of AD brain [46], was prevented in  
captopril-treated Tg2576 mice (Figure 8b). 
2.9. Captopril Treatment Reduced Markers of Amyloidogenic Processing of APP 
ROS promotes the amyloidogenic processing of Aβ by enhancing β-secretase- and  
γ-secretase-mediated APP cleavage [7,47]. In addition, brain angiotensin II infusion enhanced the 
activities of β- and γ-secretase by AT1 receptor stimulation [45]. In agreement with a ROS/angiotensin  
II-dependent effect on β-secretase activity, enzyme activity measurement showed that the  
captopril-mediated decrease in hippocampal ROS/angiotensin II generation was accompanied by a 
significant decrease in β-secretase activity, i.e., β-secretase activity was 55.7% ± 10.8% lower in 
captopril-treated mice compared to untreated 18 month-old Tg2576 mice (Figure 9a). Concomitantly, 
the hippocampal content of the N-terminal fragment of APPSwe generated by β-secretase cleavage 
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[sAPPβ (sw)] was significantly reduced of captopril-treated Tg2576 mice compared to untreated  
18 month-old Tg2576 mice (Figure 9b). 
Figure 9. Captopril treatment reduced markers of amyloidogenic processing of APP.  
(a) Hippocampal β-secretase activity of 18 month-old Tg2576 mice treated without or with 
captopril (ACEI) for six months as indicated (±s.d.; n = 4 mice/group; ** p = 0.0019);  
(b) Hippocampal content of sAPPβ (sw) of 18 month-old Tg2576 mice (Tg-18mo) treated 
without or with captopril (ACEI) for six months was determined by immunoblot with 
sAPPβ (sw)-specific antibodies (±s.d.; n = 4 mice/group; ** p = 0.0038); (c) Hippocampal 
microarray gene expression data of Klotho (Affymetrix ID: 1423400_at; ±s.d.;  
n = 2 gene chips/group with RNA from four mice pooled for one gene chip; A,B p < 0.01 vs. 
Tg-12mo; C p < 0.001 vs. Tg-18mo; ANOVA and Tukey’s Multiple Comparison Test);  
(d) Determination of hippocampal Klotho protein level by quantitative immunoblotting 
(±s.d.; n = 4 mice/group; A p < 0.001 vs. Tg-12mo and B p < 0.001 vs. Tg-18mo; ANOVA 
and Tukey’s Multiple Comparison Test); (e) Hippocampal γ-secretase activity of  
18 month-old Tg2576 mice treated without or with captopril (ACEI) for six months as 
indicated (±s.d.; n = 4 mice/group; *** p = 0.0008); (f) Immunoblot quantification of 
hippocampal AICD content of 18 month-old Tg2576 mice (Tg-18mo) treated without or 
with captopril (ACEI) for six months (±s.d.; n = 4 mice/group; ** p = 0.0021). Middle and 
lower panels show representative immunoblot detections of AICD and APP; (g) Hippocampal 
microarray gene expression data of Transgelin (Affymetrix ID: 1423505_at; ±s.d.; n = 2 
gene chips/group with RNA from four mice pooled for one gene chip;  
A p < 0.05 vs. Tg-12mo; and B p < 0.05 vs. Tg-18mo; ANOVA and Tukey’s Multiple 
Comparison Test); (h) Determination of hippocampal Transgelin protein level by 
quantitative immunoblotting (±s.d.; n = 4 mice/group; A p < 0.001 vs. Tg-12mo and  
B p < 0.001 vs. Tg-18mo; ANOVA and Tukey’s Multiple Comparison Test); (i) 
Immunoblot detection of Aβ peptides in guanidine-extracted hippocampal tissue of  
18 month-old Tg2576 (Tg-18mo) mice treated without or with captopril (ACEI) for  
six months (n = 4 mice/group); (j) Quantitative determination of SDS-insoluble 
hippocampal Aβ1-40 and Aβ1-42 content of 18 month-old Tg2576 (Tg-18mo) mice treated 
without or with captopril (ACEI) for six months (±s.d.; n = 4 mice/group; *** p = 0.0006 
and ** p = 0.0029). 
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We asked whether the hippocampal gene expression profile reflected the captopril-induced change 
in β-secretase activity of Tg2576 mice. To this end, we focused on Klotho because the N-terminal 
fragment of APP generated by β-secretase cleavage (sAPPβ) is reported to induce the transcription of 
Klotho [48]. In parallel to the decrease in β-secretase activity, captopril treatment led to a significantly 
reduced hippocampal expression and protein level of Klotho compared to age-matched untreated 18 
month-old Tg2576 mice (Figure 9c,d). Together these findings indicate that the captopril-induced 
decrease in ROS/angiotensin II level was accompanied by reduced β-secretase-activity, which could 
account for decreased amyloidogenic processing of APP. 
After APP cleavage by β-secretase, cleavage by γ-secretase finally releases Aβ. In agreement with 
ROS/angiotensin II-dependent enhancement of γ-secretase activity [7,45], hippocampal γ-secretase 
activity of captopril-treated mice was significantly reduced by 52.5% ± 7.5% compared to age-matched 
untreated AD mice (Figure 9e). In agreement with decreased γ-secretase activity, the hippocampal 
content of the APP intracellular domain (AICD), which is the C-terminal product of γ-secretase 
cleavage of APP, was significantly lower of captopril-treated 18 month-old Tg2576 mice compared to 
age-matched untreated AD mice (Figure 9f). Since increasing evidence suggests that AICD contributes 
to AD pathogenesis by promoting signs of neurodegeneration [49], that observation could indicate that 
the neuro-regenerative profile of captopril could be partially attributed to a decrease of AICD. 
Searching for signs of γ-secretase activity in the hippocampal gene expression profile, we focused 
on Transgelin because previous data had shown that the γ-secretase-mediated C-terminal cleavage 
product of APP, i.e., the APP intracellular domain (AICD), triggers the expression of Transgelin [50]. 
Concomitantly with a decrease in γ-secretase activity, the expression level of Transgelin was 
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significantly lower in captopril-treated Tg2576 mice compared to age-matched untreated Tg2576 mice 
(Figure 9g). Immunoblot analysis confirmed the gene expression data and showed that captopril had 
prevented the AD-induced rise in Transgelin protein level of aged 18 month-old Tg2576 mice  
(Figure 9h). 
Reduced amyloidogenic processing of APP upon captopril treatment was also reflected by the level 
of hippocampal Aβ peptides. Immunoblot detection showed a significantly lower level of Aβ peptides 
in hippocampal tissue extracts of captopril-treated Tg2576 mice relative to age-matched untreated 
controls (Figure 9i). Quantitative assessment of SDS-insoluble Aβ peptides by ELISA confirmed the 
decrease in hippocampal Aβ1-40 and Aβ1-42 peptides upon captopril treatment (Figure 9j). 
2.10. Model of Vicious Cycle of Angiotensin II-Dependent Aβ Generation 
Taken together our data present strong evidence that captopril retarded the aging-dependent 
accumulation of Aβ plaques in brain of Tg2576 mice by mediating a decrease of β- and  
γ-secretase-dependent amyloidogenic processing of APP. Concomitantly, treatment with the centrally 
active ACE inhibitor captopril could slow the development of signs of neuronal degeneration in the 
Tg2576 mouse model of AD. In view of previous data demonstrating that ACE is induced by 
aggregated Aβ in vitro and in vivo [43,44], our findings suggest a vicious cycle, which seems to 
contribute to disease progression in AD: (i) Augmented Aβ level of AD brain induces ACE [43,44]. 
(ii) The increased ACE protein generates angiotensin II. (iii) Angiotensin II stimulates AT1-dependent 
ROS generation and enhances amyloidogenic APP processing by β- and γ-secretase [7,45,47], thereby 
accelerating Aβ-mediated ACE induction and angiotensin II-AT1-dependent Aβ generation  
(Figure 10). Captopril treatment could interfere with that vicious cycle by normalizing ACE protein 
level and activity. This effect could account for decreased angiotensin II-dependent ROS generation, 
and reduced amyloidogenic processing of APP and Aβ generation in AD mice. While our study 
provided evidence for a beneficial effect of captopril in the Tg2576 mouse model, future studies are 
needed to determine the impact of the angiotensin II system on the Aβ-induced neurodegenerative 
process of other experimental AD models or AD patients. 
Figure 10. ACE seems to be part of a vicious cycle of angiotensin II-AT1-dependent  
Aβ generation. 
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3. Experimental Section  
3.1. Animal Model of AD and Captopril Treatment 
The study used male Tg2576 mice on a C57BL/6J (B6) background, which expresses the human 
APP695 isoform with the Swedish double mutation (APP695K670N,M671L; APPSwe) under control of the 
neuron-specific prion protein promoter [37]. Treatment with captopril or enalapril (20 mg/kg/day or  
25 mg/kg/day in drinking water, dissolved fresh every day) was initiated at 12 months of age when Tg2576 
mice start to develop substantial Aβ plaque load and signs of overt neurodegeneration [20,21,37]. ACE 
inhibitor treatment was well tolerated, and the applied doses are effective in mice as documented by 
previous studies [38,51]. Treatment of Tg2576 mice was performed for six months, from  
12–18 months of age. As control groups, we used 18 month-old Tg2576 mice, which received drinking 
water without ACE inhibitor, and 12 month-old Tg2576 mice. Mice were randomly assigned to 
different treatment groups. All mice were kept on a 12 h light/12 h dark regime, had free access to food 
and water, and were fed a standard rodent chow. At the end of the observation period, Tg2576 mice 
were anesthetized with ketamine and xylazine (100 mg/kg and 10 mg/kg, i.p.), perfused intracardially 
with sterile PBS, brains were isolated, and hippocampi were dissected and immediately frozen in 
liquid nitrogen or processed for further use. Animal experiments were performed in accordance with 
NIH guidelines, and were reviewed and approved by the local committee on animal care and use 
(University of Zurich, Switzerland). 
3.2. Whole Genome Microarray Gene Expression Profiling 
Whole genome microarray gene expression profiling of hippocampal gene expression was 
performed similarly as described [38,39]. Briefly, total RNA was isolated from mouse hippocampi by 
a commercial kit (RNeasy mini kit, Qiagen GmbH, Hilden, Germany), hippocampal RNA was reverse 
transcribed and processed for whole genome microarray gene expression profiling according to the 
protocol of the manufacturer (Affymetrix GeneChip Expression Analysis Technical Manual, rev. 5, 
Affymetrix Inc., Santa Clara, CA, USA). Fragmented, biotin-labeled cRNA (15 μg/gene chip) was 
hybridized to the microarray gene chip (Affymetrix GeneChip Mouse Genome MG430 2.0 Array with 
more than 45,000 probe sets), in 200 μL of hybridization solution in a Hybridization Oven 640 
(Affymetrix Inc., Santa Clara, CA, USA) at 45 °C for 16 h. Gene chips were washed and stained using 
Affymetrix Fluidics Station 450 according to the GeneChip Expression Analysis Technical Manual. 
Microarrays were scanned with the Affymetrix GeneChip Scanner 7G, and signals were processed 
with a target value of 600 using GCOS (version 1.4, Affymetrix Inc., Santa Clara, CA, USA). 
Our study of whole genome expression profiling of hippocampal genes from aged 18 month-old 
Tg2576 mice is without precedent, i.e., to date, hippocampal whole genome microarray gene 
expression data of aged 18 month-old Tg2576 mice are not available in the NCBI GEO database 
(search terms: Tg2576 and hippocampus). Due to the low amount of hippocampal tissue, hippocampal 
RNA from four Tg2576 mice was pooled for one gene chip, and two gene chips are presented for each 
group. Such an approach is valid because the inter-individual variability of inbred mouse lines is 
negligible as was analyzed for the Tg2576 model with RNA from brain cortex [52]. Another study 
with AD mice, which used 12 month-old Tg2576 mice (GSE1556), i.e., the age of our control group, 
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was also performed in duplicates [53,54]. Moreover, transgenic expression of a disease-causing gene 
(i.e., APPSwe) and identical (inbred) genetic background (B6) accounts for a well-defined time course 
of disease progression of Tg2576 mice.  
Selection criteria for differentially expressed genes (p ≤ 0.01, just alpha, no false discovery 
correction, and a two-fold change requirement) were specifically validated for chemical (drug) 
treatment effects and follow the guidelines of the MicroArray Quality Control (MAQC) project for the 
identification of reproducible gene lists [55,56]. Probe sets with significant difference (p ≤ 0.01, and 
≤−2-fold or ≥+2-fold difference, with call present and/or signal intensity ≥100) between treated 
Tg2576 mice relative to age-matched untreated Tg2576 mice were used for GO classification. Gene 
ontology (GO) analyses of microarray data were performed with GCOS-processed data using 
GeneSpring GX software (Agilent Technologies Inc., Santa Clara, CA, USA). Results were supported 
by RMA-normalized data (not shown). Major conclusions based on microarray data were validated by 
immunohistological and immunoblotting techniques performed with different groups of mice.  
All microarray gene expression data are available at the NCBI GEO database (accession  
number GSE46871).  
3.3. Biochemical Analyses 
ACE activity measurement of homogenized hippocampal tissue was performed with a fluorogenic 
substrate (Abz-FRK(Dnp)-P) according to the specifications of the manufacturer (Biomol International, 
Enzo Life Sciences AG, Lausen, Switzerland) in the absence and presence of captopril as  
described [28]. Activities of β-secretase and γ-secretase of homogenized hippocampal tissue were 
measured with fluorogenic substrates for each secretase (Calbiochem) as detailed previously [45]. 
Hippocampal angiotensin II level was determined by immunoblot after Tricine-SDS-PAGE with 
antibodies specific for angiotensin II displaying minimal crossreactivity with angiotensin I (<1%), as 
described [57]. Hippocampal content of Epha4 was determined by direct binding assay with  
anti-Epha4 antibodies followed by detection with 125I-labeled secondary antibodies (1.0 μCi/point; 
final concentration 5 × 10−8 M) similarly as described [20]. Binding assays were performed in 
triplicates with crude homogenates (0.5 mg of protein/mL) prepared from dissected hippocampi of  
12 and 18 month-old Tg2576 mice, respectively, treated for six months without or with captopril or 
enalapril as indicated.  
3.4. Immunohistology, Immunofluorescence and Immunoblotting 
For immunohistology, paraffin-embedded brain sections (8 μm, taken at 50 μm intervals,  
10–15 sections/set) were prepared from the different groups of Tg2576 mice. Sections were 
deparaffinized followed by antigen retrieval as detailed previously [20,57]. Immunohistological 
detection of ACE, AT1, and Epha4 was performed with F(ab)2 fragments of affinity-purified 
polyclonal antibodies pre-absorbed to mouse tissue. Sections were stained for Aβ plaques with 
monoclonal antibodies cross-reacting with residues 1–12 of the Aβ peptide (clone BAM-10;  
Sigma-Aldrich, St. Louis, MO, USA). All sections were imaged with a Leica DMI6000 microscope 
equipped with a DFC420 camera. Plaque burden of the different study groups was analyzed by 
computerized quantitative image analysis of immuno-stained hippocampal areas [20]. 
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Immunofluorescence and dihydroethidium (DHE) staining were performed with cryo-sections (8 μm) 
of post-fixed and frozen brains obtained from the different study groups of Tg2576 mice. Sections 
were imaged with a confocal laser microscope (Leica TCS SPE). For co-localization studies of AT1 
(or ACE) with Aβ, affinity-purified rabbit anti-AT1 antibodies (or rabbit anti-ACE antibodies) and 
monoclonal mouse Aβ antibody were applied (dilution 1:4000), followed by secondary antibodies 
labeled with Alexa Fluor 488 and Alexa Fluor 546, respectively (dilution of 1:5000; Molecular Probes, 
Life Technologies Corp., Carlsbad, CA, USA). Immunoblot detection of hippocampal proteins was 
performed with the guanidine hydrochloride-extracted protein fraction (6.25 M guanidine 
hydrochloride in 50 mM Tris, pH 8.0), similarly as described [20,21]. The hippocampal content of the 
APP intracellular domain (AICD), an APP cleavage product generated by γ-secretase, was determined 
by immunoblot with anti-APPCter antibodies after separation of cytosolic hippocampal proteins by 
Tricine-SDS-PAGE. SDS-insoluble, formic acid (70%)-extractable Aβ1-40 and Aβ1-42 content of 
hippocampi was determined by ELISA after serial tissue extraction in the presence of protease 
inhibitors as described [20]. Hippocampal 3-nitrotyrosine content was quantified by slot blot with  
3-nitrotyrosine-specific antibodies (Sigma) similarly as described [58].  
3.5. Antibodies 
The following antibodies were used for immunohistology, immunofluorescence and immunoblotting: 
anti-ACE antibodies (raised in rabbit against an antigen corresponding to amino acids 720–750 of 
mouse ACE), anti-AT1 antibodies (raised in rabbit against an antigen corresponding to amino acids 
306–359 of the mouse Agtr1a sequence), anti-Epha4 antibodies (raised in rabbit against an antigen 
corresponding to amino acids 917–927 of mouse Epha4), anti-Gnag2 antibodies (raised in rabbit 
against recombinant Gnag2), anti-Gnaq/11 antibodies (raised in rabbit against the C-terminus of  
Gnaq; [20]), anti-Kcnc1 antibodies (raised in rabbit against an antigen corresponding to amino acids 
567–585 of mouse Kcnc1), anti-Klotho antibodies (raised in rabbit against an antigen corresponding to 
amino acids 998–1014 of mouse Klotho), anti-Rab6b antibodies (raised in rat against recombinant 
mouse Rab6b fusion protein), anti-Scn1a antibodies (raised in rabbit against an antigen corresponding 
to amino acids 465–481 of mouse Scn1a), anti-Transgelin antibodies (raised in rabbit against residues 
16–90 of mouse Transgelin). Aβ plaques were stained with monoclonal anti-Aβ antibody (monoclonal 
antibody cross-reacting with residues 1–12 of the Aβ peptide; clone BAM-10, Sigma), sAPPβ (sw) 
was detected with a monoclonal antibody (6A1) specifically recognizing the β-secretase-cleaved end 
of APPSwe, and immunoblot detection of AICD was performed with anti-APPCter antibodies raised in 
rabbit against an antigen corresponding to residues 676–695 of APP695. Antibody specificity and 
cross-reactivity with the respective protein were routinely controlled by ELISA, immunoblotting and 
immunofluorescence applying the antigen used for immunization and cell lysates, or cells  
over-expressing the respective target gene.  
3.6. Statistical Analysis 
Unpaired two-tailed Student’s t-test was used to calculate p values. For comparisons between  
more than two groups, analysis of variance was performed with Prism (GraphPad) or TIGR MeV, 
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followed by a Post-test as indicated. Statistical significance was set at a p value of <0.05 unless 
indicated otherwise. 
4. Conclusions  
Aβ plaque accumulation in the hippocampus of AD mice was retarded by treatment with the 
centrally active ACE inhibitor, captopril. Concomitantly, captopril promoted signs of neuronal 
regeneration as evidenced by gene expression profiling and immunohistological analyses. Treatment 
effects of captopril were accompanied by normalization of the AD-related increase in ACE  
protein level and activity, decreased accumulation of hippocampal angiotensin II and reduced ROS 
generation. In addition, the amyloidogenic processing of APP by β- and γ-secretase was decreased in 
captopril-treated AD mice. Together with previous studies [43–45], our data suggest a vicious cycle of 
Aβ-dependent ACE induction, ACE-dependent angiotensin II release, angiotensin II AT1 receptor 
activation-dependent ROS formation, which in turn promotes Aβ generation by enhancing the 
amyloidogenic processing of APP [7,45,47]. The thereby stimulated release of Aβ is expected to 
further up-regulate ACE [43,44] and to trigger a new round of angiotensin II-mediated Aβ generation 
(Figure 10). 
Clinical evidence indicates beneficial effects of long-term antihypertensive treatment with a 
centrally active ACE inhibitor regarding retardation of the onset of cognitive decline [34]. The present 
study complements those data and suggests a synergism between beneficial vascular effects and 
inhibition of angiotensin II-promoted APP processing—at least in individuals with enhanced 
angiotensin II generation. Since the ACE protein level is also increased in the brains of patients with 
Alzheimer’s disease, and all components of the angiotensin-AT1 receptor system are present in 
different regions of the human brain [27,28,43], future studies will have to determine whether the 
neuro-regenerative potential of captopril documented in AD mice could be also of relevance for 
individuals at risk of developing cognitive impairment or AD.  
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